Skip to Content

Azacitidine was generally well tolerated in patients ≥ 75 years of age in QUAZAR AML-001

A subgroup analysis from QUAZAR AML-001 presented at EHA 2021 shows that maintenance treatment with azacitidine was generally well tolerated in all age groups, including elderly (≥75 years) AML patients. Also, the study shows improvement in survival by 14.9 months compared with placebo and in progression-free survival by 7.9 months for this group of patients.

Lue artikkeli

Jos olet lääkäri, farmaseutti tai rajatun lääkkeenmääräämisoikeuden omaava sairaanhoitaja, pääset lukemaan artikkelin kirjautumalla käyttäjäksi BestPractice Nordic -sivustolle.

Back to top